» Articles » PMID: 35018747

Vitamins A, D, E Status As Related to Supplementation and Lung Disease Markers in Young Children with Cystic Fibrosis

Overview
Date 2022 Jan 12
PMID 35018747
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The variable response to fat-soluble vitamin supplementation in young children with cystic fibrosis (CF), and factors contributing to this variability, remain under-investigated.

Objective: To determine if recommended supplement doses normalize serum vitamins A (retinol), D (25-hydroxy-vitamin D, 25OHD), and E (α-tocopherol), and identify factors predictive of achieving sufficiency, in children with CF in the first 3 years of life.

Design: We studied 144 infants born during 2012-2017 and diagnosed with CF through newborn screening. Serum retinol, 25OHD, α-tocopherol and plasma cytokines interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor (TNF)-α were measured in early infancy and yearly thereafter. Vitamin supplement intakes and respiratory microbiology were assessed every 1-2 months in infancy and quarterly thereafter.

Results: The prevalence of vitamin D insufficiency (<30 ng/ml) at all ages combined was significantly higher (22%) compared to vitamin A (<200 ng/ml, 3%) and vitamin E (<5 µg/ml, 5%). All children were vitamin A sufficient by age 2 years. Vitamin E insufficiency was rare. Only 42% were early responders of vitamin D and 17% remain insufficient despite high supplement intakes. IL-6 was positively correlated, while IL-8, IL-10, and TNF-α were negatively correlated, with retinol and 25OHD. Multiple regression analysis revealed that supplement dose, season, α-tocopherol, pancreatic insufficiency, respiratory infections and IL-10 were significant predictors of 25OHD.

Conclusion: Diagnosis through newborn screening coupled with supplementation normalized serum retinol and α-tocopherol in almost all infants with CF by age 3 years. However, response to vitamin D supplements in young children with CF occurred later and variably despite early and sustained supplementation.

Citing Articles

The Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis.

Huang L, Lai H, Furuya K, Antos N, Asfour F, Boyne K Pediatr Pulmonol. 2025; 60(3):e71042.

PMID: 40071665 PMC: 11898569. DOI: 10.1002/ppul.71042.


Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.

Liu C, Bach T, Farrell P, Pavelec D, Antos N, Rock M J Pediatr Gastroenterol Nutr. 2024; 79(6):1124-1133.

PMID: 39465618 PMC: 11615133. DOI: 10.1002/jpn3.12389.


Vitamin D status and variable responses to supplements depend in part on genetic factors in adults with cystic fibrosis.

Braun A, Lai H, Laxova A, Biller J, Hubertz E, Zhao Z J Cyst Fibros. 2024; 23(4):754-757.

PMID: 38383231 PMC: 11624284. DOI: 10.1016/j.jcf.2024.02.005.


Impact of intrinsic and extrinsic risk factors on early-onset lung disease in cystic fibrosis.

Huang L, Lai H, Song J, Zhao Z, Lu Q, Murali S Pediatr Pulmonol. 2023; 58(11):3071-3082.

PMID: 37539852 PMC: 10592256. DOI: 10.1002/ppul.26625.


Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators.

Francalanci M, Terlizzi V, Fevola C, Di Rosa G, Pierattini V, Roselli E Children (Basel). 2023; 10(2).

PMID: 36832382 PMC: 9955178. DOI: 10.3390/children10020252.


References
1.
Karohl C, Su S, Kumari M, Tangpricha V, Veledar E, Vaccarino V . Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr. 2010; 92(6):1393-8. PMC: 2980965. DOI: 10.3945/ajcn.2010.30176. View

2.
Marcus M, Sondel S, Farrell P, Laxova A, Carey P, Langhough R . Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. Am J Clin Nutr. 1991; 54(3):578-85. DOI: 10.1093/ajcn/54.3.578. View

3.
de Vries J, Chang A, Bonifant C, Shevill E, Marchant J . Vitamin A and beta (β)-carotene supplementation for cystic fibrosis. Cochrane Database Syst Rev. 2018; 8:CD006751. PMC: 6513379. DOI: 10.1002/14651858.CD006751.pub5. View

4.
Borowitz D, Baker S, Duffy L, Baker R, FitzPatrick L, Gyamfi J . Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 2004; 145(3):322-6. DOI: 10.1016/j.jpeds.2004.04.049. View

5.
Okebukola P, Kansra S, Barrett J . Vitamin E supplementation in people with cystic fibrosis. Cochrane Database Syst Rev. 2017; 3:CD009422. PMC: 6464074. DOI: 10.1002/14651858.CD009422.pub3. View